BioMarin Pharmaceutical

BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. The efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. Our track record of developing and commercializing new treatments has been significantly faster than the industry average and is a remarkable accomplishment that is ingrained in our culture. The company's product portfolio comprises five marketed products and multiple clinical and pre-clinical product candidates.

San Rafael, US
Size (employees)
2,293 (est)+7%
BioMarin Pharmaceutical was founded in 1997 and is headquartered in San Rafael, US

BioMarin Pharmaceutical Office Locations

BioMarin Pharmaceutical has offices in San Rafael, Novato, Kronberg im Taunus, Cork and in 28 other locations
San Rafael, US (HQ)
770 Lindaro St
Mocoa, CO
96 Cra. 9
London, GB
10 Bloomsbury Way
Leiden, NL
Biopartner Gebouw 1 21 J.H. Oortweg
Dublin, IE
Saint James House Adelaide Rd
Kronberg Im Taunus, DE
28 Westerbachstraße
Novato, US
105 Digital Dr

BioMarin Pharmaceutical Data and Metrics

BioMarin Pharmaceutical Financial Metrics

BioMarin Pharmaceutical's revenue was reported to be $1.1 b in FY, 2016 which is a 26% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

1.1 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

907.2 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(630.2 m)

EBIT (FY, 2016)

(803.4 m)

Market capitalization (28-Apr-2017)

16.6 b

Closing share price (28-Apr-2017)


Cash (31-Dec-2016)

408.3 m
BioMarin Pharmaceutical's current market capitalization is $16.6 b.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


548.5 m751 m889.9 m1.1 b

Revenue growth, %


Cost of goods sold

95.7 m129.8 m152 m209.6 m

Gross profit

452.7 m621.3 m737.9 m907.2 m

Gross profit Margin, %


Operating expense total

608.8 m843.9 m1 b1.9 b


(156 m)(92.9 m)(110.7 m)(803.4 m)

EBIT margin, %


Interest expense

10.4 m36.6 m38.2 m39.5 m

Interest income

3.1 m5.9 m4.5 m7.5 b

Pre tax profit

(176.5 m)(124.9 m)(154.7 m)(831.1 m)

Income tax expense

(150 k)9.1 m17.1 m(200.8 m)

Net Income

(176.4 m)(134 m)(171.8 m)(630.2 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


568.8 m875.5 m397 m408.3 m

Accounts Receivable

117.8 m144.5 m165 m215.3 m


162.6 m199.5 m271.7 m355.1 m

Current Assets

1.1 b1.4 b1.1 b1.4 b


319.3 m523.5 m704.2 m798.8 m


54.3 m54.3 m197 m197 m

Total Assets

2.2 b2.5 b3.7 b4 b

Current Liabilities

183.3 m235.7 m445.5 m439.3 m

Additional Paid-in Capital

2.1 b2.4 b3.4 b4.3 b

Retained Earnings

(715.8 m)(849.8 m)(1 b)(1.5 b)

Total Equity

1.3 b1.5 b2.4 b2.8 b

Financial Leverage

1.7 x1.6 x1.6 x1.5 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(176.4 m)(134 m)(171.8 m)(630.2 m)

Depreciation and Amortization

47.3 m56.7 m47.2 m96.9 m

Accounts Receivable

(8.8 m)(27 m)(16 m)(51 m)


(34 m)(37 m)(51 m)(65 m)

Cash From Operating Activities

(59.6 m)(73.5 m)(221.7 m)(227.8 m)

Purchases of PP&E

(65.1 m)(118.8 m)(227.7 m)(148.4 m)

Cash From Investing Activities

(298.8 m)194.6 m(1.2 b)(484 m)

Cash From Financing Activities

746.7 m185.7 m927.9 m727.1 m

Income Taxes Paid

14.9 m35 m16.1 m95.9 m
Y, 2016

Financial Leverage

1.5 x

BioMarin Pharmaceutical Operating Metrics

BioMarin Pharmaceutical's Patent Applications was reported to be 426 in FY, 2016
FY, 2016

Phase 1/2


Phase III Trials


Patents Issued

1.17 k

Patent Applications


BioMarin Pharmaceutical Market Value History

BioMarin Pharmaceutical Revenue Breakdown

BioMarin Pharmaceutical Job Categories

BioMarin Pharmaceutical Median Salaries

Source: 52 public H-1B filings from BioMarin Pharmaceutical

BioMarin Pharmaceutical News and Updates

BioMarin Pharmaceutical Company Life and Culture

You may also be interested in